Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025European Heart Journal Supplements

Comparison of apixaban 5 mg vs 2.5 mg for the prevention of cancer-associated venous thromboembolism: A pooled analysis of two studies

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMichael SabinaVMVikas MalhotraSPShivangi Patel

Discussion

Loading...

Member takes

Implication

Meta-analysis compares efficacy and safety of 2.5 mg vs 5 mg apixaban in cancer patients, suggesting safety in dose reduction.

Key Points

  • No significant difference in VTE recurrence or major bleeding risk was found between apixaban doses in cancer patients.
  • Recurrent venous thromboembolism rates showed no statistical significance with RR 0.73 between dosing regimens.
  • Data was derived from one randomized controlled trial and one observational study, including 854 patients overall.
  • Additional randomized controlled trials are necessary to further evaluate long-term anticoagulation strategies.

Cite This Study

Sabina et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64793a16https://doi.org/10.1093/eurheartjsupp/suaf083.198
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced‐Dose Versus Full‐Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta‐Analysis of Randomized Trials2025 · 3 citations
  2. 2Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis2026
  3. 3Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel2025 · 3 citations
  4. 4Comparison of the Safety and Effectiveness of Apixaban Versus Rivaroxaban in Acute Venous Thromboembolism: A Propensity-Matched Real-World TriNetX Study with Obesity and Cancer Subgroup Analyses2026
  5. 5Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial2025 · 2 citations